This study was designed to increase the throughput of rat brain microdialysis studies by administration of compounds as a cassette as opposed to discrete study. Eight compounds (carbamazepine, citalopram, desmethylclozapine, diphenhydramine, gabapentin, metoclopramide, naltrexone, and stavudine) were selected and administered as an intravenous bolus dose at 0.5-3.3 mg/kg each followed by an intravenous infusion at 1 mg/kg per hour for 6 hours in rats in a cassette or discrete dosing. The dialysate, plasma, brain, and cerebrospinal fluid were collected and analyzed using liquid chromatography-tandem mass spectrometry. The microdialysis probe recovery was determined by an in vitro gain method. The recovery between the cassette and discrete dosing was similar, with an average of 1.0 6 0.10-fold difference. The stavudine interstitial fluid (ISF) concentration, as measured by brain microdialysis, was below the low limit of quantitation and was excluded from the analyses. The ratios of ISF concentration to unbound plasma concentration were within 2-fold for six of the remaining seven compounds, with an average of 0.92 6 0.51-fold difference between the cassette and discrete methods. The ratios of ISF concentration to unbound brain concentration, as measured by the brain homogenate method, were also similar, with a 1.1 6 0.7-fold difference. In addition, the ratios of ISF to cerebrospinal fluid concentrations were similar, with a 1.5 6 0.6-fold difference. The results from this study support the use of a cassette dosing approach to enhance the throughput of rat brain microdialysis studies in drug discovery.
Introduction
The blood-brain barrier (BBB), which is formed from cerebral endothelia, and the blood-cerebrospinal fluid (CSF) barrier, which is formed from choroid plexus epithelia, protect the brain from toxins in the blood and from variations in blood composition (Davson and Segal, 1995) . The two main factors that limit the delivery of drugs from blood into the brain are the low paracellular permeability of the BBB and the multiple drug transporters expressed at the BBB and the blood-CSF barrier. These factors lead to a disparity between the unbound drug concentration in plasma and the unbound drug concentration in the brain (Schinkel et al., 1994; Chen et al., 2003; Breedveld et al., 2005; Enokizono et al., 2007; Gazzin et al., 2008; Liu et al., 2008; Polli et al., 2009; Zhou et al., 2009; Kodaira et al., 2010; Agarwal et al., 2011) . Therefore, to evaluate the brain penetration of drugs and examine the pharmacokinetic and pharmacodynamic relationships of drugs in the brain, the unbound drug concentration in the organ needs to be measured directly. This information is crucial for compounds with targets localized in the central nervous system (CNS) and when a high drug concentration in the brain must be achieved in order for the drug to interact with receptors. Conversely, these data are required when brain exposure must be limited for non-CNS compounds to avoid or reduce CNS-mediated side effects (Liu et al., 2008) .
Various methods have been used to determine the unbound brain concentration of a drug de Lange and Hammarlund-Udenaes, 2015) . The two protocols used in our study are the brain homogenate method and the brain microdialysis method. In this study, the unbound brain concentration measured by the brain homogenate method is denoted as the unbound brain concentration (C ub ) , and the unbound brain concentration measured by brain microdialysis is denoted as the interstitial fluid (ISF) concentration (C ISF ). Brain microdialysis is considered the gold standard approach (Chaurasia et al., 2007) . This method has been used extensively in nonclinical studies to determine the unbound drug concentration in brain tissue and has even been used in the clinic to monitor glucose metabolism and the lactate and pyruvate ratio as a marker for ischemia in patients with brain trauma (Hillered et al., 2006; Helmy et al., 2007; Zielke et al., 2009; Notkina et al., 2012; Bossers et al., 2013) . This method, however, has not been widely used in drug discovery to assess drug brain penetration mainly because of the method's low throughput and the high nonspecific binding of highly lipophilic compounds that are often encountered in drug discovery.
This study was designed to investigate whether the throughput for brain microdialysis can be increased by using a cassette dosing approach. Cassette dosing has been widely used in the investigation of pharmacokinetics in drug discovery (Manitpisitkul and White, 2004; Liu et al., 2012 Liu et al., , 2014 and of drug-drug interactions in clinical trials (http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM292362. pdf). We recently observed that the risk for drug-drug interactions in cassette dosing was low, even when specific P-glycoprotein (P-gp) and breast cancer resistant protein (BCRP) substrates and potent specific inhibitors were included in a single cassette (Liu et al., 2014) . Up to now, however, no report has assessed the utility of the cassette approach in a brain microdialysis study. In this study, rat brain microdialysis was conducted for eight compounds: carbamazepine, citalopram, desmethylclozapine, diphenhydramine, gabapentin, metoclopramide, naltrexone, and stavudine. There compounds were selected because they represent structurally diverse compounds with different physicochemical properties. In addition, their rat brain microdialysis results have been reported. Both discrete dosing and cassette dosing were used for all eight compounds to examine whether a difference exists between these two approaches. In addition, in vitro plasma binding and in vitro recovery for the microdialysis probe were performed, and the values were compared between the discrete and cassette methods.
Materials and Methods
Chemicals. Carbamazepine, citalopram, desmethylclozapine, diphenhydramine, gabapentin, metoclopramide, naltrexone, and stavudine were obtained from Sigma-Aldrich (St. Louis, MO). All chemicals used in the experiments were of the highest available grade.
Plasma and Brain Protein Binding. The unbound fractions in plasma and brain homogenate for the eight compounds were determined in a 48-well rapid equilibrium dialysis device using a dialysis membrane with a molecular mass cutoff value of 8000 Da (Pierce Biotechnology, Rockford, IL). Blank plasma and brain homogenate, prepared as one part brain and three parts water, were spiked with the eight compounds at a final concentration of 5 mM. A total of 300 ml plasma with compound was added to the donor side and 500 ml buffer was added to the receiver side. The plate was placed on a rocking platform at 400 rpm with 1-mm radius agitation for 4 hours at 37°C. A volume of 20 ml each of buffer and plasma samples was transferred to a 96-well plate, and 20 ml of blank plasma and buffer was added to the buffer and plasma samples, respectively. Plasma proteins were precipitated using 65% acetonitrile containing internal standard (0.1 mM propranolol). Drug concentrations were quantitated by high-performance liquid chromatography-tandem mass spectrometry, and the unbound fraction in plasma (f up ) and unbound fraction in the brain homogenate (f u,homogenate ) were calculated as a ratio of buffer concentration to plasma concentration.
The unbound fraction in brain tissues was estimated from the unbound fractions determined in the brain tissue homogenates using eq. 1 (Kalvass and Maurer, 2002) :
where f ub represents the unbound fraction in brain tissue and D is the dilution factor for the brain homogenate.
In Vitro Recovery of the Microdialysis Probe. The probe and tubing were preconditioned by rinsing them with 10 ml artificial CSF solution (Harvard Apparatus, Holliston, MA). Recovery of the microdialysis probes was determined using a gain method (Liu et al., 2009 ). Briefly, a 12/2-mm probe (CMA Microdialysis, Solna, Sweden) was immersed in a 1.5-ml tube with the artificial CSF solution at 37°C containing 100 ng/ml of one compound for the discrete approach or 100 ng/ml of a mixture of the eight compounds for the cassette approach. The probe was perfused with the artificial CSF solution at 1 ml/min for 6 hours. The dialysate was collected every 0.5 hour and stored at 220°C before analysis. The ratio of the concentration in the dialysate versus that in the solution was calculated as the in vitro recovery.
Brain Microdialysis. Jugular and femoral-cannulated male Sprague-Dawley rats (250-350 g, aged 8 to 9 weeks), with a surgically implanted microdialysis guide cannula and a dummy probe (CMA/12; CMA Microdialysis), were purchased from Charles River Laboratories, Inc. (Wilmington, MA). After the rats were anesthetized, the guide cannula was implanted in the prefrontal cortex of the rat brains using a stereotaxic instrument at 3.2 mm anteroposterior, 1.0 mm mediolateral, and 0.5 mm dorsoventral to the bregma point and secured to the skull with screws and dental cement. The animals were acclimatized to the laboratory environment for 3-5 days before the study. At approximately 16 hours before dosing, the rats were placed into individual BASi RATURN systems (Bioanalytical Systems, Inc., West Lafayette, IN) and were freely moving animals with food and water ad libitum. The dummy probes were replaced with CMA 12/2-mm probes (CMA Microdialysis) and perfused with an artificial CSF solution (CMA Microdialysis) at 1 ml/min overnight using microdialysis pumps (CMA/102; CMA Microdialysis). On the day of the study, the outlets were connected to the BASi Refrigerated HoneyComb Fraction Collector (Bioanalytical Systems, Inc) at 4°C and perfused at 1 ml/min. Rats (n = 4) received an intravenous bolus dose via the femoral cannula for carbamazepine (1.5 mg/kg), citalopram (3.3 mg/kg), desmethylclozapine (0.75 mg/kg), diphenhydramine (1 mg/kg), gabapentin (2 mg/kg), metoclopramide (0.5 mg/kg), or naltrexone (1 mg/kg) followed by intravenous infusion at 1 mg/kg per hour in either discrete or cassette doses. No intravenous bolus dose was given for stavudine. The formulation vehicle was saline. Blood samples were collected via the jugular vein cannula at 0.25, 1, 2, 4, 5, and 6 hours after start of infusion. Blood was then centrifuged to obtain plasma. The perfusate samples were serially collected from each animal at 0.5-hour intervals from 0 hours predose to 6 hours postdose. At 6 hours, the animals were euthanized a Calculated pK a using Moka software (version 2.0) (Milletti et al., 2007) . by intravenous injection of 750 mg/kg phenobarbital and 95 mg/kg phenytoin sodium solution (Euthasol; Virbac Corporation, Fort Worth, TX). Approximately 100-ml CSF samples were collected via cisterna magna puncture from each rat. Brain samples were also collected. All of the samples were stored at 220°C before analysis. All studies were approved by the Genentech Institutional Animal Care and Use Committee. Sample Analysis. Standard curves and quality control samples were prepared by spiking a known amount of a mixture of the eight compounds into a blank mixed matrix of rat plasma, brain homogenate, or CSF. The brain tissue of each rat was homogenized in 4 volumes (w/v) of water. A total of 25 ml of samples, 25 ml of calibration standards, or 25 ml of quality controls was mixed with 5 ml internal standard (9-hydroxyrisperidone) and 200 ml acetonitrile. After vortexing and centrifugation at 1500 Â g for 10-15 minutes, 100 ml supernatant was transferred to a 96-well plate and diluted with 50 ml water prior to analysis by high-performance liquid chromatography-tandem mass spectrometry.
Samples were analyzed using two sets of standard curves and two sets of quality controls in each analytical run. The system consisted of a Shimadzu LC-20AD pump (Shimadzu, Columbia, MD), an HTS-PAL autosampler (Leap Technologies, Switzerland), and an AB Sciex API 4000 (AB Sciex, Foster City, CA) mass spectrometer with a turbo ion spray interface. A 20-ml aliquot of each sample was injected onto a reverse-phase PFP 2.6m 100A 50 Â 2.1-mm column (Phenomenex, Torrance, CA). The lower limit of quantitation ranged from 0.8 to 2.0 ng/ml. The assay accuracy was between 75% and 125%.
Data Analysis. The total brain drug concentration was corrected for the residual blood in the brain vasculature by subtracting 1.03% of the plasma concentration determined in the corresponding samples (Fridén et al., 2010) . The brain and plasma unbound concentrations are calculated by eqs. 2 and 3:
where C p , C up , C b , and C ub represent the total plasma, unbound plasma, total brain, and unbound brain concentrations, respectively, and f up and f ub represent the fraction unbound in plasma and brain, respectively.
Results
In Vitro Binding and Microdialysis Probe Recovery Using Cassette and Discrete Approaches. The physicochemical properties for the eight compounds are presented in Table 1 . The plasma and brain unbound fractions of the eight compounds are listed in Table 2 . For the eight compounds, the fractions measured in the discrete and cassette approaches were similar. Mean (6 S.D.) differences between the cassette and discrete approaches were 1.3 6 0.5-fold for the plasma unbound fraction and 1.2 6 0.6-fold for the brain unbound fraction. The in vitro recoveries of the eight compounds determined in the cassette and discrete methods are listed in Table 3 . For all eight compounds, the recovery in the cassette and discrete methods was similar, with a 1.0 6 0.1-fold difference. These binding and recovery differences are not significantly different from unity (P . 0.05, t test), indicating that cassette and discrete dosing approaches produce similar results for the binding and probe recovery.
Plasma and ISF Concentrations after Cassette and Discrete Dosing. The unbound plasma concentration and the ISF concentration after cassette and discrete dosing are shown in Fig. 1 . The concentrationtime profiles were generally similar between the cassette and discrete dosing. Higher carbamazepine, citalopram, and stavudine concentrations were observed in the cassette dosing approach compared with discrete dosing. This difference may be attributable to interexperimental variability and/or potential systemic drug-drug interactions. The concentration-time profiles demonstrate that steady-state drug concentration was achieved at approximately 1 hour after initiation of the intravenous bolus injection and intravenous infusion for both plasma and brain tissue. dmd.aspetjournals.org
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Comparision of the C ISF /C up , C ISF /C ub , and C ISF /C CSF Ratios after Cassette and Discrete Dosing. The drug concentrations in ISF, plasma, brain, and CSF at the end of the 6-hour study are listed in Table 4 . The ISF and CSF concentrations for stavudine were below the lower limit of quantitation, so only seven compounds have a full data set and are included in the analyses. The C ISF /C up , C ISF /C ub , and C ISF /C CSF ratios observed from the cassette and discrete dosing are listed in Table 5 and shown in Fig. 2 . The C ISF /C up ratios between the two methods were within 2-fold for six of the seven compounds, with a 0.92 6 0.51-fold difference. The C ISF /C ub ratios were also similar, with a 1.1 6 0.7-fold difference. In addition, the C ISF /C CSF ratios were similar, with 1.5 6 0.6-fold difference. These ratios are not significantly different from unity (P . 0.05, t test), indicating that cassette and discrete dosing rat brain microdialysis studies generate similar results.
Discussion
Our previous work supports the use of cassette dosing to assess brain penetration of drug candidates in drug discovery (Liu et al., 2012 (Liu et al., , 2014 . One of the main concerns with using cassette dosing in such studies is that the potential inhibition of drug transporters at the BBB may interfere with the results; however, we found that inhibition of drug transporters such as P-gp or Bcrp at the BBB was not observed even in a cassette containing typical P-gp or Bcrp substrates and potent P-gp and Bcrp inhibitors. This conclusion is consistent with observed low unbound plasma concentrations of these inhibitors in these studies (Liu et al., 2012 (Liu et al., , 2014 .
This study extends the utility of the cassette dosing approach from a conventional brain penetration study to a rat brain microdialysis study. In drug discovery, brain penetration is commonly assessed by determination of the in vivo area under the curve of the brain and plasma concentration-time profiles, calculated from single-dose or steady-state brain and plasma concentrations, and by determination of the unbound fractions in plasma and brain homogenate (Liu et al., 2008; Hammarlund-Udenaes et al., 2009 ). The unbound brain concentration (C ub ) and the unbound plasma concentration (C up ) are then estimated from the in vivo brain and plasma concentrations and their corresponding unbound fractions. From these values, we can calculate the unbound brain to unbound plasma concentration ratio (k p,uu ) as C ub /C up . A k p,uu value of unity indicates that no drug transport is involved at the BBB, a k p,uu that is less than unity indicates that efflux transport is involved, and a k p,uu that is greater than unity indicates that uptake transport is involved.
Brain microdialysis is considered the gold standard for determination of drug concentration in the brain ISF and represents a theoretically superior way to determine the k p,uu as C ISF /C up . This method, however, has not gained wide use in drug discovery and development because of its low throughput and the extensive nonspecific binding of highly lipophilic compounds (de Lange and Hammarlund-Udenaes, 2015) . Our study was designed to overcome the limitation of low throughput by use of a cassette dosing approach. Our data show, for the first time, that cassette dosing is a feasible approach in rat brain microdialysis. The C ISF /C up ratio, which is the most important parameter determined from brain microdialysis studies, is consistent between cassette and discrete dosing methods ;   TABLE 4 Observed ISF, unbound plasma, unbound brain, and CSF concentrations at 6 hours after cassette and discrete dosing of eight compounds Data are presented as the mean 6 S.D. (n = 4).
Compound
Cassette Discrete dmd.aspetjournals.org likewise, the C ISF /C ub and C ISF /C CSF ratios are also similar between both dosing methods. Furthermore, the in vitro recovery, plasma protein binding, and brain homogenate binding are all comparable between the cassette and discrete methods. There is a trend that C ISF is higher than C ub. The underlying mechanism could be that compounds are excluded from cells to some degree or bind to sites in the brain homogenate that are not accessible in intact brain tissue (Becker and Liu, 2006) . Another protocol, the brain slice method, has been proposed as a more accurate way of determining the unbound fraction in the brain, avoiding this complication with the brain homogenate method (Becker and Liu, 2006; Fridén et al., 2007) .
Our data on plasma and brain unbound fractions and on C ISF /C up from the brain microdialysis are, in general, consistent with data reported in the literature (Ludden et al., 1976; Wang and Welty, 1996; Yang et al., 1997; Burattini et al., 2008; Fridén et al., 2009; Liu et al., 2009; Sadiq et al., 2011) . The only exception is C ISF /C up for diphenhydramine. Sadiq et al. (2011) observed a C ISF /C up value of approximately 5.5 for diphenhydramine, but our observed ratios were near unity in both cassette and discrete dosing studies. The underlying mechanism for this discrepancy remains to be examined.
In summary, the in vivo and in vitro studies reported here show that similar brain penetration results are obtained by dosing drugs as a cassette or as individual compounds in rat brain microdialysis studies. These results support the use of cassette dosing to increase throughput in such studies, thus addressing one of the two main obstacles that limit the use of brain microdialysis studies in drug discovery. Additional research is required to optimize brain microdialysis to reduce nonspecific binding and enable the study of highly lipophilic compounds by this method. 
